OUR SERVICES

Our Process

OUR Products

CONCIERGE SERVICES

In Vitro Testing

In Vivo Testing

Qualification & Tech Transfer

Clinical Testing

Search
Search
Generic filters
Services
Products
Type the name of a target, pathogen, service, assay or catalog number

DISEASE TARGET

IBT has a plethora of reagents, assays or services based on disease targets.

ANIMAL SERVICES

DISTRIBUTION PARTNERS

ARTICLES

Emerging viral threats often stem from viral mutations, which can enhance a virus’s ability to infect hosts, evade immune responses, or become more virulent. An unfortunate example of this is the COVID-19 pandemic, which has fundamentally changed how we live and function as a population. While detrimental, this event has

One of the most powerful applications of flow cytometry is for evaluating drug and vaccine efficacy. Multiparameter flow cytometry relies on the use of fluid systems, fluorescent proteins, and optical systems to detect and collect fluorophore signals. When the technology first became available multiparameter meant 2 colors, today it can

The increasing rate of bacterial resistance creates a challenging environment for the development of therapies for bacterial infections. Bacterial skin infections are one of the leading manifestations of infectious diseases in the world. Staphylococcus aureus—both Methicillin-resistant (MRSA) and Methicillin-Sensitive (MSSA) strains—is the leading cause of skin and soft tissue infections

NEWS

New Monoclonal Antibody Under Development to Combat Marburg Virus [Rockville, MD, April 2025] A promising new therapeutic is being developed to address the urgent need for effective treatments for Marburg virus disease (MVD), a highly fatal viral infection. Currently, no FDA-approved medical countermeasures (MCMs) exist for the treatment of Marburg

IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services [Maryland, January 2024] – IBT Bioservices, a renowned figure in the Biocapital region’s life sciences landscape, proudly announces its rebranding from Integrated Biotherapeutics. Effective February 2023, IBT Bioservices unveils a revitalized identity, reinforcing its commitment to excellence in Contract Research

IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the regulatory challenges and opportunities when moving a product from pre-clinical to clinical stage. The live webinar scheduled for Sept. 24, 2020 will feature experts on various aspects of antimicrobial resistance

Search
Generic filters